William J. Muller

Active 1983–2025

174
Papers
30,414
Citations
100
h-index
170
i10-index

Citations

Citations per year for William J. Muller1984: 4 citations1985: 7 citations1986: 3 citations1987: 5 citations1988: 15 citations1989: 25 citations1990: 33 citations1991: 24 citations1992: 38 citations1993: 19 citations1994: 28 citations1995: 47 citations1996: 52 citations1997: 49 citations1998: 67 citations1999: 131 citations2000: 212 citations2001: 234 citations2002: 195 citations2003: 270 citations2004: 262 citations2005: 275 citations2006: 262 citations2007: 314 citations2008: 298 citations2009: 362 citations2010: 339 citations2011: 284 citations2012: 262 citations2013: 275 citations2014: 291 citations2015: 240 citations2016: 192 citations2017: 201 citations2018: 197 citations2019: 629 citations2020: 903 citations2021: 883 citations2022: 617 citations2023: 550 citations2024: 938 citations2025: 417 citations2026: 10 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,488 citing papers, 34.1% of this breakdownChina: 1,304 citing papers, 9.9% of this breakdownCanada: 795 citing papers, 6% of this breakdownUnited Kingdom: 740 citing papers, 5.6% of this breakdownItaly: 500 citing papers, 3.8% of this breakdownGermany: 493 citing papers, 3.7% of this breakdownFrance: 413 citing papers, 3.1% of this breakdownSpain: 367 citing papers, 2.8% of this breakdownJapan: 335 citing papers, 2.5% of this breakdownAustralia: 308 citing papers, 2.3% of this breakdownSwitzerland: 256 citing papers, 2% of this breakdownIndia: 231 citing papers, 1.8% of this breakdown
0%34.1%Other 22.4%

Fields

  • Biochemistry, Genetics and Molecular Biology46%
  • Medicine42.1%
  • Immunology and Microbiology7.1%
  • Neuroscience1%
  • Computer Science0.8%
  • Engineering0.5%
  • Other2.5%

Topics

  • Cancer Cells and Metastasis3.2%
  • Cell Adhesion Molecules Research2.4%
  • Cancer, Hypoxia, and Metabolism2.4%
  • COVID-19 Clinical Research Studies2.1%
  • PI3K/AKT/mTOR signaling in cancer2.1%
  • HER2/EGFR in Cancer Research2%
  • Other85.8%

Coauthors

All papers

Open in search
  1. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 976

  2. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Child & Adolescent Health 2023 cited by 318

  3. Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 238

  4. Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer

    Authors: , , , , , , , , , , , , , , - Cancer Cell 2013 cited by 859

  5. The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer

    Authors: , , , , , , , , , , , , , , , - Immunity 2023 cited by 183

  6. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.

    Authors: , , - Molecular and Cellular Biology 1992 cited by 1,540

  7. Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo

    Authors: , , , - Oncogene 2020 cited by 233

  8. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)

    Authors: , , , , , , , , , , , , , , , , - Clinical Infectious Diseases 2022 cited by 201

  9. Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kelly Hautzinger, Bethany Girard, Karen Slobod, Roderick McPhee, Rolando Pajón, Anne Aunins, Rituparna Das, Jacqueline M. Miller, Sabine Schnyder Ghamloush - New England Journal of Medicine 2022 cited by 141

  10. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)

    Authors: , , , , , , , , , , , , , , - Clinical Infectious Diseases 2020 cited by 1,069

  11. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cell Biology 2008 cited by 699

  12. Oncogenes and Tumor Suppressor Genes

    Authors: , - Cold Spring Harbor Perspectives in Biology 2010 cited by 507

  13. Noninvasive Diagnosis of Infection Using Plasma Next-Generation Sequencing: A Single-Center Experience

    Authors: , , , , , , - Open Forum Infectious Diseases 2019 cited by 127

  14. Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season

    Authors: , , , , , , , , , , , , , , , - Journal of the Pediatric Infectious Diseases Society 2024 cited by 47

  15. The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression

    Authors: , , , , , , , , , , , , , , - Cell Reports 2018 cited by 144

  16. Trastuzumab/pertuzumab combination therapy stimulates antitumor responses through complement-dependent cytotoxicity and phagocytosis

    Authors: , , , , , , , , , , , , - JCI Insight 2022 cited by 44

  17. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2021 cited by 61

  18. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3

    Authors: , , , , , , , , , , , , , - Oncogene 2014 cited by 254

  19. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase

    Authors: , , , , - Nature Communications 2013 cited by 223

  20. Cell‐free DNA next‐generation sequencing successfully detects infectious pathogens in pediatric oncology and hematopoietic stem cell transplant patients at risk for invasive fungal disease

    Authors: , , , , , - Pediatric Blood & Cancer 2019 cited by 106

  21. ESR1 mutant breast cancers show elevated basal cytokeratins and immune activation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 72

  22. Suppression of tumor growth and metastasis in Mgat5-deficient mice

    Authors: , , , , , - Nature Medicine 2000 cited by 566

  23. Targeted disruption of β1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction

    Authors: , , , , , , - Cancer Cell 2004 cited by 409

  24. Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jaime Tasayco-Muñoz, Sue J. Hong, William J. Muller, Matthew Doerfler, Cydni N. Williams, Kurt Drury, Dhristie Bhagat, Aaron Nelson, Dana C. Price, Heda Dapul, Laura Jurema dos Santos, Robert J. Kahoud, Conall Francoeur, Brian Appavu, Kristin P. Guilliams, Shannon C. Agner, Karen Walson, Lindsey Rasmussen, Anna Janas, Peter Ferrazzano, Raquel Farias‐Moeller, Kellie Snooks, Chung‐Chou H. Chang, James Yun, Michelle E. Schober - Pediatric Neurology 2021 cited by 106